List of Daytrana drug patents

Daytrana is owned by Noven Pharms Inc.

Daytrana contains Methylphenidate.

Daytrana has a total of 3 drug patents out of which 0 drug patents have expired.

Daytrana was authorised for market use on 06 April, 2006.

Daytrana is available in film, extended release;transdermal dosage forms.

Daytrana can be used as method for transdermally delivering a drug to a user in need thereof.

The generics of Daytrana are possible to be released after 07 October, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers
Oct, 2025

(2 years from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 06 April, 2006

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of DAYTRANA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in